By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.

Contact Information

Website: www.atyrpharma.com
Email: investorrelations@atyrpharma.com
Main Phone: +1 858 731-8389
Address: 3545 John Hopkins Court
Address 2: Suite 250
State: CA
City / Town: San Diego
Country: US
Postal Code: 92121

Issuer Information

Exchange: NSC
CEO: Sanjay S. Shukla
Employees: 44
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

View More
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A